In the 2011 review, EGCG was shown to become an androgen antagonist; when included to prostate most cancers cells, EGCG physically interacted Along with the androgen receptor’s ligand-binding area.[20] In another review, nude mice have been injected with human prostate cancer cells and handled with intraperitoneal injections of docetaxel, lycopen